Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial

  title={Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial},
  author={Pierre Amarenco and Alfred S. Callahan and Vito M. Campese and Larry B. Goldstein and Michael Hennerici and Michael Messig and Henrik Sillesen and K. Michael A. Welch and Daniel J. Wilson and Justin A. Zivin},
Background and Purpose— Higher low-density lipoprotein cholesterol is associated with more rapid chronic kidney disease progression; reduction in cholesterol with statins, in conjunction with statins’ pleiotropic effects, such as decreasing inflammation, may be renoprotective. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial assessed the effect of statin treatment on the risk of nonfatal and fatal stroke in subjects with a noncardioembolic stroke or transient… 

Figures and Tables from this paper

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
In patients treated with atorvastatin, higher HDL cholesterol levels were associated with lower risk of eG FR decline in patients with normal eGFR at baseline, however, further study is needed to establish whether there is any causal relationship between HDLs and renal function.
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial
Intensive management of dyslipidemia in older patients with stable coronary heart disease may have beneficial effects on renal function and SUA.
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events)
Clopidogrel plus aspirin could decrease new stroke in patients with normal kidney function and mild CKD, but no extra benefit was observed in those with moderate CKD.
Renal Function-Dependent Associations of Statins with Outcomes of Ischemic Stroke
In patients with acute ischemic stroke, the associations of statins with mortality and functional outcomes was dependent on eGFR, and using statins at discharge was correlated with a lower risk of unfavorable functional outcomes.
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Current evidence points towards the need to prescribe high-potency statins in patients with CKD, before a major decline in kidney function occurs, which may reduce CVD risk and delay the progress of CKD.
Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose‐dependent manner and was strongly associated with lower cardiovascular risk.
High Dose of Atorvastatin for the Treatment of Contrast-Induced Nephropathy After Carotid Artery Stenting
Pretreatment with 40 mg of atorvastatin is both effective and safe in preventing CIN after CAS and Adverse events of the live and heart should be closely monitored during atorVastatin treatment.
LDL-cholesterol lowering and renal outcomes
  • D. Waters
  • Medicine, Biology
    Current opinion in lipidology
  • 2015
In large trials, statin-treated patients have slightly less worsening of renal function overtime, and there are data to suggest that statins actually do not only preserve, but also increase renal function.
High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
High-intensity statin therapy could effectively reduce the risk of stroke in patients with CKD, however, its effects on all-cause mortality, myocardial infarction, heart failure and renal protection remain unclear.


Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Pravastatin modestly reduced the rate of kidney function loss in people with or at risk for cardiovascular disease, however, the primary indication for the use of statins in peoplewith or at high risk for coronary events remains the reduction in mortality that results from their use.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Estimated GFR improved in both treatment groups but was significantly greater with 80 mg than with 10 mg, suggesting this benefit may be dosage related, and the expected 5-yr decline in renal function was not observed.
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
In hypertensive patients with moderate dyslipidemia and decreased eGFR, pravastatin was not superior to usual care in preventing clinical renal outcomes, however, benefit from statin therapy may depend on the degree of the cholesterol level decrease achieved.
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
It is concluded that pravastatin may slow renal function loss in individuals with moderate to severe kidney disease, especially those with proteinuria, with more benefit in those with lower MDRD-GFR at baseline.
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
It is shown that treatment with atorvastatin in addition to a regimen with ACE inhibitors or ARBs may reduce proteinuria and the rate of progression of kidney disease in patients with chronic kidney disease, proteinuria, and hypercholesterolemia.
Effects of lowering LDL cholesterol on progression of kidney disease.
Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD and showed no significant effect on the rate of change in eGFR.
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
In untreated dyslipidaemic patients with CHD and normal renal function at baseline, CrCl declines over a period of three years and statin treatment prevents this decline and significantly improves renal function, potentially offsetting an additional factor associated withCHD risk.